Anti-Mouse IL-2 (Clone: JES6-5H4) – Purified In vivo GOLD™ Functional Grade
Pricing & Details
Purified Recombinant Mouse IL-2 (>98%)
≥ 5.0 mg/ml
<1.0 EU/µg as determined by the LAL method
≥95% monomer by analytical SEC
>95% by SDS Page
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Clone JES6-5H4 recognizes an epitope on mouse IL-2.
IL-2 is a 17.2 kD cytokine signaling protein that is the regulator of the proliferative and suppressive phases of the immune response, and stimulates growth and differentiation of B cells, NK cells, LAK cells, monocytes, and oligodendrocytes. It functions as a primary regulator of T cell homeostasis. Il-2 regulates the activities of white blood cells and plays a role in the immune system via “self” and “non-self” discrimination. IL-2 is a prime candidate in immunotherapeutics for both increasing T cell levels/function and for augmenting vaccine-elicited viral-specific T cell responses. IL-2 signal can be transduced via 3 different signaling pathways that include the JAK-STAT, PI3K/Akt/mTOR and MAPK/ERK pathways. Aldesleukin is a form of recombinant interleukin-2 for the treatment of cancers including malignant melanoma and renal cell cancer. Furthermore, there is additional therapeutic potential for IL-2 mAb use with transplants and autoimmune disease.
NCBI Gene Bank ID
References & Citations
1. Schachter, J. et al. (2009) Cytotherapy 11: 206
2. Sodora, DL. et al. (2009) Curr HIV Res. 7: 83
3. Alcocer-Varela, J. et al. (2009) Autoimmun Rev. 9(1):34-9.
Products are for research use only. Not for use in diagnostic or therapeutic procedures.